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ABSTRACT
Objective: Few studies have been conducted in Kentucky to investigate the statewide
prevalence of HCV infection and its associated risk factors. The purpose of this study was
to examine the factors related to HCV infection in the state, and specifically to investigate
geographical differences of HCV infection between those residing in Appalachian vs. NonAppalachian counties in Kentucky.
Methods: The study sample (n =5205) was selected from a pool of 8300 high-risk
individuals participating in a pilot cross-sectional study on HCV conducted by the
Kentucky Department for Public Health. The pilot study involved serologically testing
participants for antibodies against HCV infection and having participants complete an
interview-administered questionnaire at the same time to examine behavioral and sociodemographic characteristics related to HCV infection. Univariate, bivariate, and logistic
regression analyses were carried out using SPSS and maps were produced using ArcGIS
software. Frequency distribution, adjusted odds ratios (AORs), and corresponding 95%
confidence intervals (95% CIs) were reported.
Results: Of the 5205 participants selected (2241 males, 2964 females; mean age,
30.4 ± 10.5 years); 9.8% tested positive for anti-HCV antibodies. Residence in
Appalachian vs. Non-Appalachian Kentucky was not significantly associated with HCV
antibody status. In the multivariate analysis, Blacks (AOR: 0.42, 95% CI: 0.26 – 0.66) and
men who have sex with men (MSM) (AOR: 0.36, 95% CI: 0.17 – 0.73) were significantly
less likely to be HCV positive after adjusting for all other variables. HCV seropositivity
was positively associated with age (AOR: 1.03, 95% CI: 1.02 – 1.04), history of injection
drug use (IDU) (AOR: 41.27, 95% CI: 31.94 – 53.31), and presence of tattoos (AOR: 1.49,
3

95% CI: 1.14 – 1.96). Gender was also found to significantly modify the association
between residence and HCV antibody status, specifically in the Appalachian region.
Conclusion: This was the first statewide analysis to examine the prevalence of HCV
infection among high-risk population residing in Appalachia vs. Non-Appalachian counties
in Kentucky. The main variables associated with HCV infection in these regions were age,
Black race, history of IDU, MSM and presence of tattoos. Addressing these risky behaviors
and particular populations through age- and gender-specific preventive and treatment
measures may reduce the high prevalence of HCV infection in the state of Kentucky.
However, more research is required to further characterize HCV-related risk factors with
respect to residence in Appalachian vs. Non-Appalachian to determine how these measures
can be effectively implemented.

Keywords: Hepatitis C virus; Kentucky; injection drug use; Appalachian vs. NonAppalachian residence
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INTRODUCTION
An estimated 1.6%, roughly 4.1 million of the United States (US) population is
affected by Hepatitis C virus (HCV) infection (Armstrong et al., 2006; Kramer et al., 2010).
Approximately 80% of this population is chronically infected with HCV, which equates to
over 3.2 million people (Armstrong et al., 2006); three-quarters of whom were born during
1945 through 1965 (CDC, 2015). National surveillance data from 2013 indicate an
incidence rate of 0.7 cases per 100,000 in the US (CDC, 2015). The highest incidence was
observed among people 20 to 29 years of age (CDC, 2015). In 2013, 19,368 deaths were
attributed to HCV-related events in the US (CDC, 2015).
Approximately three-quarters of people infected with HCV are asymptomatic (CDC,
2015). Symptoms, if present, are nonspecific. The acute phase of HCV infection, which is
defined by laboratory confirmation, is short-term and those infected present either with no
symptoms or mild symptoms including jaundice and/or elevated alanine aminotransferase
greater than 400 IU/L (Suryaprasad, 2014). Of those infected, over 40-50% recover
spontaneously and the rest progress into a chronic phase of the infection. Untreated HCV
infection persists for 20-30 years resulting in advanced liver disease (Zignego et al., 2012).
This includes liver fibrosis, cirrhosis, liver failure, and ultimately hepatocellular carcinoma
(El-Serag and Mason, 2000; Thomas and Seeff, 2005). Currently, HCV is the most
common cause of chronic liver disease and leading cause of liver transplantation in the US
(Alter, 2007; Gordon et al., 2009; Rustgi, 2007; Searson et al., 2014).
The predominant route of HCV transmission in the US is percutaneous exposure to
contaminated blood and other blood products. Populations identified at risk for HCV
infection include injection drug users (IDU) and occupational exposure to blood via
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needlestick injuries, those undergoing invasive medical procedures, the homeless
population, men who have sex with men (MSM), those with human immunodeficiency
virus (HIV), inmates in correctional facilities, persons born between 1945 and 1965, and
people who misused alcohol (Alter, 2007; CDC, 2015; Missiha et al., 2008; Searson et al.,
2014). HCV infection is not efficiently transmitted via sex. However, engaging in rough
sex, sex with multiple sexual partners, and engaging in high-risk sexual practices such as
unprotected anal sex among MSM, are associated with increased risk of HCV infection
(CDC, 2015; McFaul et al., 2014).
The implementation of universal precautions to prevent transmission of blood-borne
infections by different establishments including hospitals has resulted in a progressive
decline in the incidence of acute HCV infection in the US (CDC 2015; CDC, 1988). Yet,
state surveillance data reports from 2006-2012 obtained from NNDSS (2014) revealed
significant increases in cases of acute HCV infection for Kentucky, Tennessee, Virginia,
and West Virginia. In 2012, these three states accounted for an estimated 20.4% of acute
HCV cases reported, with 4.1 cases per 100,000 reported in Kentucky alone compared to
the national rate of 0.7 cases per 100,000 (CDC, 2015). These data show a drastic increase
of acute HCV infection in Kentucky to 4.1 cases per 100,000 from 0.7 cases per 100,000
reported by the state in 2007 (CDC, 2015). Notably, many Kentuckians are likely unaware
of their HCV infection status due to most infections being asymptomatic as well as the lack
of available resources for screening and testing high-risk individuals throughout the state.
Previous studies have focused on assessing the association between several risk
factors and HCV infection mostly in rural Appalachian regions in Kentucky. The rate of
HCV infection in Appalachian Kentucky has been found to be strongly associated with
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IDU (Christian et al., 2010). According to Havens and colleagues (2013) the prevalence of
HCV infection among people who inject drugs (PWID) in Appalachian Kentucky was
estimated at 54.6%, which was similar to results from other smaller studies in the region
(Christian et al., 2010) and national data (Armstrong et al., 2006). Havens and colleagues
(2013) also identified several factors associated with HCV infection including herpes
simplex virus 2 (HSV-2), injection of cocaine, injection of prescription opioids, injecting
for at least 5 years, posttraumatic stress disorder, and recent sharing of syringes. These risk
factors such as injecting drugs have also been associated with active HCV infection (HCV
RNA positivity) (Young et al., 2012).
Research has shown than the high rates of HCV infection can be observed in young
PWID, predominantly White adults, residing in or near Appalachian jurisdictions
(Suryaprasad et al., 2014). This study demonstrated that the incidence of acute HCV
infection in the US was highest in those less than 30 years of age residing in rural areas
east of the Mississippi River in five states, among which, Kentucky had the highest rate.
Results from Suryaprasad and colleagues (2014), and Zibbell and colleagues (2015)
indicated the rates of HCV infection to be more than double amongst young PWID less
than 30 years of age, residing in or near Appalachian regions compared to young PWID
residing in Non-Appalachian urban areas.
This study seeks to further explore the Appalachian vs. Non-Appalachian
disparities in the epidemiology of HCV infection. The study utilized data obtained from
the first statewide study ever conducted in Kentucky to assess the risk factors associated
with HCV infection. The purpose of this study was to examine the risk factors related to
HCV infection in Kentucky, and specifically to test the hypothesis that HCV infection
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would be more prevalent among residents of Appalachian Kentucky compared to those
residing in Non-Appalachian Kentucky.

MATERIALS AND METHODS
Study Design and Population
The Kentucky Adult Viral Hepatitis Prevention Coordinator (KY-AVHPC)
established the Kentucky Viral Hepatitis Coalition, a multidisciplinary team that includes
Kentucky Department for Public Health (KDPH) staff, infection preventionists, and
regional epidemiologists from local health departments, substance abuse treatment center
program managers, KY Department of Corrections medical director, Kentucky Primary
Care Association director, primary care providers and networks, and hepatologists and
infectious disease specialists for the treatment of viral hepatitis in Lexington and
Louisville.
Kentucky received permission in April 2012 to conduct a pilot laboratory testing
project for HCV infection in 37 selected local health departments (LHD) jurisdictions.
LHDs were given guidelines for screening and obtaining blood samples from high-risk
individuals for HCV antibody and RNA testing to determine those exposed to HCV
infection. Data was also administered through interview-administered questionnaires. The
eligibility criteria for the pilot study included being at least 18 years of age, a resident of
Kentucky, history of IDU, lifetime history of multiple sexual partners, or lifetime history
of STD. Patients presenting with active liver disease of any cause were excluded from the

8

study. This pilot project lasted from May 1, 2012 to October 31, 2014. This compiled data
were reported to the Viral Coordinator at KDPH.
By the end of the study, 8300 high-risk individuals underwent interviewadministered questionnaires and had blood samples drawn at the same time at different
substance abuse clinics, STD clinics, rehabilitation centers, and other treatment centers
within local health departments. The dried blood sample specimens collected by finger
stick were submitted to the Kentucky State Public Health Laboratory for analysis. This
analysis focused on screening the participants for the presence of anti-HCV antibodies
using an enzyme immunoassay (EIA) test (sensitivity: 91.8%; specificity 98.2%)
(Chernesky et al., 2001). Blood specimens from those with anti-HCV antibodies were
referred to one of two national reference laboratories (Quest Diagnostics or LabCorp – KY)
to carry out the HCV RNA confirmatory test using the recombinant immunoblot assay
(RIBA) test from May 2012 to mid-June 2013 and the quantitative real-time polymerase
chain reaction (PCR) RNA test from mid-June 2013 to October 2014. During the transition
from RIBA to PCR testing, RNA testing was not performed for an unknown number of
HCV antibody positive specimens, and also the sensitivity and specificity differed between
the RIBA and PCR tests; thus, limiting reliable aggregation of the results. Therefore, RNA
results were excluded from this analysis.
At the start of the pilot study, the KDPH did not have a Viral Hepatitis Coordinator
employed to receive the completed questionnaires and test results. In addition, the State
Laboratory could store data for only 6 months. As a result, most of the initial data collected
in the first 6 months of the pilot study were lost. By the end of the study, the total compiled
data at KDPH included 5300 completed questionnaires and test results. Of the 5300, 29
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were tests performed on individuals who resided outside of Kentucky and 66 surveys were
missing responses from all the behavioral survey questions and part of the demographic
survey questions. Thus, these were excluded from analysis, leaving a final sample size of
5205.

Questionnaire Survey and Data Collection
The interviewer-administered questionnaires were developed by the KDPH, based
on knowledge of potential risk factors associated with HCV infection and with the guidance
and advice from regulatory officials and viral hepatitis coordinators working in other states.
A trained staff member at each center or local health department interviewed the high-risk
individuals using the questionnaire to obtain information on socio-demographics (age,
gender, race, ethnicity, and home address zip code), risk behavior (MSM, lifetime history
of multiple sexual partners, history of IDU, and presence of tattoos), and medical history
(HIV status and lifetime history of STD). The hard copy completed surveys were sent to
the Viral Hepatitis Coordinator at the KDPH. This information and test results were
compiled in Microsoft Excel 2013 software.

Statistical Analysis
SPSS, version 22 (IBM Corp) were used for the analysis and ArcGIS mapping
software was used to create maps. Descriptive statistics were reported as frequency and
percentages for categorical variables; and as means and standard deviations for continuous
variables. The only continuous variable in this study was age. The categorical variables
included gender, race, ethnicity, history of IDU, lifetime history of multiple sex partners,
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MSM, lifetime history of STD, presence of tattoos, self-reported HIV status, and residence
in an Appalachian or Non-Appalachian county. Residential address zip codes were used to
determine whether or not participants resided in a county designated by the Appalachian
Regional Commission to be in an Appalachian region versus Non-Appalachian region
(ARC, 2015). The HCV prevalence by county was graphically represented in Figure 1.
Univariate and bivariate descriptive analyses were conducted to assess the
association between each independent variable (described above) with the outcome of
interest (HCV antibody status). Descriptive statistics are presented by HCV antibody status
in Table I. Logistic regression analysis was carried out to compute the crude odds ratio
and 95% confidence interval for the variables. Statistical significance was determined
using criteria of p-value <0.05. This is presented in Table I.
The next steps in the analysis used modeling to examine the association between
residence in Appalachian vs. Non-Appalachian counties and HCV antibody status. A
summary of the statistical analyses is also found under the Appendix section.
Collinearity assessment. All the variables were put into a linear model to compute
tolerance and variance inflation factor (VIF) to assess for collinearity. Collinearity would
be present with a VIF >10 and Tolerance <0.10 (Belsley et al., 2005).
Interaction assessment. Cross-tabulation for each variable by HCV antibody status
and residence in Appalachian vs. Non-Appalachian county was carried out to identify strata
with cell sizes too small (i.e. cell sizes of zero) to be analyzed in interaction terms reliably.
The variables with zero cells were excluded when assessing for interaction. Logistic
regression analysis was carried out to compute the odds ratio (OR) for each interaction
term’s association with HCV antibody status, adjusted for lower-order terms. If the
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statistical significance using p-value <0.05 was found, the interaction term was kept for the
final model.
Confounding assessment. All of the independent variables were assessed for
confounding using a 15% change criteria (Bursac et al., 2008) between the estimated crude
odds ratio obtained from the stated association (residence and HCV antibody status) and
the adjusted odds ratio obtained after adjusting for each variable as a potential confounder.
If the difference between the two measures of association was 15% or greater, then the
variable was considered a confounder and kept for the final model.
Multivariable analysis. The first multivariable logistic regression model included
the exposure variable (residence in Appalachia vs. Non-Appalachian region), all
confounding variables, interaction terms and their lower order terms, and the remaining
independent variables that were significantly associated with HCV seropositivity in the
univariate analysis in Table I. All 12 variables were run in a linear regression model to
reassess for collinearity using tolerance and VIF values. A final model examining the
variables associated with HCV antibody status was determined using backward elimination
logistic regression analysis. Backward elimination was used to sequentially remove all
variables with the highest p-values above the significant p-value <0.05, leaving only the
statistically significant variables in the final model including the confounders and
interaction terms. The adjusted odds ratio and 95% confidence intervals were computed
for the remaining variables in the final model using multivariable logistic regression.
Results are presented in Table II.
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Stratified analysis by region of residence. Logistic regression analysis was carried
out to assess the variables significantly associated with HCV antibody status in
Appalachian and Non-Appalachian counties. This was presented in Table III.

Ethics Statement
This study was approved by the Institutional Review Board of the KDPH (CHFSIRB-DPH-FY15-26) and the Institutional Review Board of University of Kentucky (150290-P3H). Informed consent was obtained from all participants in the initial pilot study.

RESULTS
Univariate and Bivariate Analyses of Socio-demographic and Behavioral Factors
Of the 5205 participants included in the analysis, 509 (9.8%) tested positive for
antibodies against HCV and 4696 (90.2%) were negative. Data from this study covered 62
out of the 120 counties in Kentucky, including 17 out of 54 total Appalachian counties and
45 out of 66 total Non-Appalachian counties. In the sample, 209 (4.0%) resided in
Appalachian counties and 4996 (96.0%) in Non-Appalachian counties. Of the 509
individuals who tested HCV positive, 28 (5.5%) resided in Appalachian counties and 481
(94.5%) in Non-Appalachian counties. Figure 1 demonstrates that the HCV positive
individuals were concentrated in the Northern part of the state, even though the
participating counties in the study were scattered throughout the state. A total of 37 out of
the 62 participating counties did not report any HCV positive case (grey-colored areas).
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The map also demonstrates that many Appalachian and Non-Appalachian counties did not
participate in the study (white-colored).
Table 1 describes demographic and behavioral characteristics. The mean age of the
HCV positive individuals was 31.9 ± 10.2 years and for HCV negative individuals,
30.2 ± 10.6 years. Approximately 43% of the participants were male. The majority (76%)
of the sample was White, 24% Black, and <1% “other” races, which in this study included
Asian and Mixed races. The participants in this study were mostly (94%) Non-Hispanic.
Overall, 14% reported a history of IDU and they accounted for 78.0% of those testing HCV
positive; 5% reported being HIV positive and 10% of those were HCV positive.
Interestingly, among MSM in the study (5% of the sample), 2.2% were HCV positive with
an odds ratio of 0.44 (95% CI: 0.24-0.80). The variables that were not significantly
associated with HCV antibody status included gender (p=0.062), “Other” race (p = 0.152),
lifetime history of STD (p = 0.812), and residence in Appalachian vs. Non-Appalachian
counties (p = 0.074).

Relationship between Appalachian versus Non-Appalachian Residence and HCV
Antibody Seropositivity
Gender was determined to be an effect modifier (interaction term OR: 2.55, 95%
CI: 1.11 – 5.88, p-value = 0.028). This indicates that for males in the study, the effect of
residing in Appalachian counties on HCV seropositivity is more pronounced than for
females residing in Appalachian counties. Results from the confounding assessment (Table
VI in Appendix) demonstrated that the strength of the association between residence in
Appalachia and HCV antibody status (crude OR: 1.45, 95% CI: 0.97 – 2.19) was decreased
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by the presence of two confounding variables: race (AOR: 1.20, 95% CI: 0.79 – 1.81), and
HIV status (AOR: 1.22, 95% CI: 0.75 – 1.96). The strength of the association between
residence in Appalachia and HCV antibody status was increased by the presence of two
confounding variables: history of IDU (AOR: 1.96, 95% CI: 1.14 – 3.37), and history of
multiple sexual partners (AOR: 1.70, 95% CI: 1.12 – 2.58). In other words, this indicates
that race and HIV status each minimize the association between residence in Appalachian
vs. Non-Appalachian and HCV antibody status by biasing the measure of association
towards the null, whereas history of IDU and history of multiple sexual partners each
exaggerate the association between residence in Appalachian vs. Non-Appalachian
counties and HCV antibody status as the effect estimate is biased away from the null.
During backward elimination, history of previous STD was removed first, followed
by ethnicity. The final model, presented in Table II, included confounders (listed above),
interaction terms and their lower order terms, and other statistically significant variables
remaining after backward elimination. Adjusting for all the other variables in the model,
significant associations were observed between HCV seropositivity and Black race (AOR:
0.42, 95% CI: 0.26 – 0.66), age (AOR: 1.03, 95% CI: 1.02 – 1.04), history of IDU (AOR:
41.27, 95% CI: 31.94 – 53.31), MSM (AOR: 0.36, 95% CI: 0.17 – 0.73), and presence of
tattoos (AOR: 1.49, 95% CI: 1.14 – 1.96). There was no significant association between
HCV antibody status and residence in Appalachian vs. Non-Appalachian counties, gender,
HIV status, history of multiple sexual partners, and “other” races compared to White race.
Interestingly, adjusting for all the variables in the final model, the odds of being HCV
positive was lower among MSM compared to non-MSM. In addition, the odds of being
HCV positive was lower in the Blacks compared to the Whites.

15

When models were stratified by residence in Appalachian and Non-Appalachian
regions, interesting patterns emerged. Table III displays correlates associated with HCV
infection among Appalachian and Non-Appalachian residents. Gender, history of IDU and
history of multiple sexual partners were the only factors found to be significantly associated
with HCV antibody status among residents in Appalachian counties. However, age, race,
ethnicity, HIV status, presence of tattoos, MSM, history of IDU and history of multiple
sexual partners were found to be significantly associated with HCV antibody status among
residents of Non-Appalachian counties. Of note, none of the independent variables were
found to be collinear, as all values for VIF were < 2 and Tolerance were > 35.

DISCUSSION
In this analysis, the association between residence in Appalachian vs. NonAppalachian counties and HCV antibody status was not statistically significant. However
several factors were found to influence the association. Race, history of IDU, HIV status,
and history of multiple sexual partners were found to confound the association between
residence in Appalachian vs. Non-Appalachian counties and HCV antibody status. In the
final model, adjusting for confounders, MSM was associated with decreased odds of HCV
infection, whereas presence of tattoos and age were associated with increased odds of HCV
infection. Of note, the variables associated with HCV seropositivity differed between the
geographic regions of Kentucky. For example, gender was associated with HCV infection
among Appalachian residents, with males having higher risk, but not associated with HCV
infection among Non-Appalachian residents. Race and MSM were associated with HCV

16

infection among Non-Appalachian residents, with Black race and MSM having lower risk,
but were not associated with HCV infection among Appalachian residents. Age and
presence of tattoos were also associated with HCV infection among Non-Appalachian
residents, with age and presence of tattoos having higher risk, but were not associated with
HCV infection among Appalachian residents. History of IDU was associated with HCV
among Appalachian and Non-Appalachian residents, with a slightly higher risk in
Appalachian residents compared to Non-Appalachian residents.
Results from the present study (Table II) demonstrated that for every one year
increase in age, the odds of HCV infection increased by 1.03, while holding all other
variables constant. In this study, the 20-29 age group accounted for the most HCV cases,
with 247 (48.5%) out of the total 509 HCV positive individuals. This finding is consistent
with previous studies, which have indicated that peak prevalence of HCV infection in the
US is observed among people aged 20-29 years of age (CDC, 2015). Of note, when the
data in the present study were stratified by gender, the positive association between age
and HCV infection was significant among males but not females.
The current study also found that the HCV prevalence was highest among White
race. This observation was similar to results obtained from the MMWR by Zibbell and
colleagues (2015), whereby non-Hispanic Whites have a greater HCV prevalence
compared to non-Hispanic Blacks. Another study had reported an epidemic of HCV
infection in the US predominantly among Whites less than 30 years of age, residing in
Appalachian counties east of the Mississippi River (Suryaprasad et al., 2014). Compared
to the White population in the present study, Blacks residing in Non-Appalachian counties
appeared to have a protective effect in being HCV positive.
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Gender was found to modify the association between residence in Appalachian vs.
Non-Appalachian counties and HCV antibody status. In crude analysis of interaction, the
association between being male and HCV positive was higher among Appalachian
residents compared to Non-Appalachian residents. Males in Appalachia had nearly three
times higher odds of being HCV positive than females, while males in Non-Appalachia did
not have significantly higher odds of being HCV positive than females. This difference
between males and females influencing the effect of HCV seropositivity can be explained
by previous studies that demonstrated that rates of HCV infection differ significantly
between gender owing to the different behavioral risks undertaken by men and women.
Research has shown that women tend to engage more in sexually-related risk behaviors
including having unprotected sex in exchange for money or drugs, whereas men tend to
engage in lifetime drug-related risk behaviors including needle sharing, and illicit drug use
such as crack cocaine (Butterfield et al., 2003).
IDU is one of the most important risk factors for HCV infection, especially among
young PWID (Alter, 2007). The results of this study supported those findings; the odds of
being HCV positive among those with a history of IDU was over forty-one times higher
than those without a history of IDU, after adjusting for the other variables in the model. In
addition, history of IDU was found to be associated with HCV infection among residents
in Appalachian and Non-Appalachian counties. These findings were consistent with other
studies, which suggested that HCV infection in Appalachian counties is highly associated
with PWID (Christian et al., 2010; Havens et al., 2013; Zibbell et al., 2015). Notably,
results from Young and colleagues (2013) indicated that turnover in individuals’ injection
networks (i.e. injecting with different individuals over time) in Appalachian Kentucky
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inferred a protective effect of HCV infection. Nonetheless, the increased rates of HCV
infections in Kentucky are likely associated with the prescription opioid epidemic among
PWID in Appalachia (Havens et al., 2013; Young et al., 2012).
Presence of tattoos as a possible risk factor for HCV infection has been researched
in previous studies. Some of these studies have shown an association between tattooing
and increased risk of HCV infection in unregulated settings where tattooing needles are
reused (Hwang et al., 2006), commercial tattoo parlors (Haley and Fischer, 2001), and
among high-risk groups such as incarcerated population where needles are shared and
reused (Hwang et al., 2006; Tohme and Holmberg, 2012), whereas other studies have failed
to produce a similar association (Hahn et al., 2001). This has been because the tattoo
measurement has varied between studies, with some studies distinguishing tattooing from
ear piercing and body piercing (Alter, 2002; Hahn et al., 2001; Hwang et al., 2006). Tattoos
in the present study were defined as presence of ink markings on the skin. In this study,
people who had a tattoo were 1.49 times the odds of having HCV infection compared to
those who did not have HCV infection after adjusting for the other variables in the model.
Notably, presence of tattoos was found to be significantly associated with HCV infection
only in Non-Appalachian counties in the state. However, information on the type and
location of the tattoos, as well as the environment and expertise of the person imprinting
the tattoos were not examined, but might be worthy of investigation in future studies.
Moreso, because this observation has been identified mostly in cross-sectional studies
(Alter, 2002; Haley and Fischer, 2001) that do not provide a temporal relationship between
tattoo exposure and HCV infection, a true causal relationship cannot be made.
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The study analysis showed that MSM have decreased odds of HCV seropositivity,
specifically in Non-Appalachian counties. Some studies (Buchbinder et al., 1994; McFaul
et al., 2014) have indicated that HCV infection is mostly found among MSM injecting
drugs and engaging in sexual activity with multiple partners. There has also been a strong
association between HCV infection and HIV-infected MSM (Workowski and Berman,
2010). This protective effect in this study could be due to increased awareness among these
population resulting in less people engaging in risk behaviors including IDU and
unprotected high-risk sexual practices. More so, this observation could be due to the small
MSM population size (n=237) in this study, of which, a smaller fraction of 11 (2.2%) tested
positive for anti-HCV antibodies. This small sample size provided a low statistical power
to detect the true effect. In addition, because the entire sample was composed of high-risk
individuals, the MSM population was being compared to other high-risk groups such as
PWID instead of the general population, which would affect its measure of association with
HCV infection (i.e. MSM are at lower risk of HCV infection compared to PWID). More
research is required to improve understanding of HCV transmission and measures currently
undertaken by MSM to reduce HCV infection risk.
Sexual transmission of HCV is uncommon, except among MSM (Workowski and
Berman, 2010). The risk of sexual transmission of HCV among monogamous couples has
been determined to be extremely rare (Karmochkine et al., 2006; Marian et al., 2003;
Rustgi, 2007). Results from Armstrong and colleagues (2006) indicate that having greater
than 20 lifetime sexual partners has been significantly associated with HCV seropositivity
in the US after controlling for age and sex, as it increases the risk of HCV infection by
fourfold. According to results from this study, having a history multiple sexual partners
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was not significantly associated with HCV infection in the univariate analysis or in the
final model. However, when stratified by the residence in Appalachian vs. NonAppalachian counties, history of multiple sexual partners was found to be independently
associated with HCV infection among residents in both Appalachian and Non-Appalachian
counties. This difference could be explained by the fact that adequate data was not available
on the number of sexual partners engaging in particular high-risk behaviors (i.e., data were
only available on whether or not they had multiple partners, not how many partners and the
risk behavior of those partners). Takeuchi and colleagues (2015) had indicated that having
HCV-infected sexual partners was significantly associated with HCV seropositivity among
men, and not among females. Interestingly, the association between multiple sexual
partners and HCV seropositivity in this study was significant only among females and not
among men for unknown reasons. Further studies are required to elucidate the association
of sexual risk behavior among men and women.

Limitations
The study had several limitations. First, data collected from the surveys was based
on self-reported behaviors. This study assumes that the information provided by the
participants was accurate and valid. However, self-reported information introduces biases
such as recall bias and information bias, specifically misclassification bias that results in
residual confounding. Second, being a cross-sectional study, previous exposure history to
the different factors does not infer causality of the HCV infection. These factors cannot be
said to cause HCV infection over time. Third, the presence of values less than 5 and missing
data in some cells in the contingency tables may impact the statistical power to detect
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associations during the stratified analysis. Fourth, selection bias may have occurred, given
that only high-risk individuals at particular centers were selected as the study population.
Fifth, 37 LHD testing sites were invited to participate; only 30 participated in this study,
suggesting that the results may not be representative of all counties in the state, especially
if the non-participating counties had a high prevalence of HCV infection, thereby affecting
the external validity of the study. Lastly, this study used only HCV antibody test results,
whereby an HCV antibody positive result meant having been infected with HCV at some
point in the past. HCV antibody status provides no information on the active or chronic
state of the infection.

Public Health Implications
The results from this study highlight opportunities for public health programs. Of
note, many counties did not participate in the cross-sectional study due to lack of resources
to carry out the HCV testing and questionnaires. Programs are thereby needed to increase
resources in those counties with insufficient resources in order to foster participation in
future HCV studies and conduct HCV surveillance. In addition, gender-specific preventive
interventions tailored towards particular geographic regions, specifically men in rural
Appalachia, can help decrease the prevalence of HCV infection in Kentucky. National
health survey data indicate that approximately 50% of HCV-infected persons in the US
have been tested for HCV, and that only 6% of those tested receive adequate treatment
(Davis et al., 2011; Munir et al., 2010). This demands implementation of primary
prevention programs, including education to professional and public institutions, effective
screening and risk-reduction counseling of high-risk individuals, referral of care to
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substance abuse treatment clinics and hospitals to improve access and increase the
proportion of high-risk individuals receiving treatment, as recommended by CDC (1998).
Reports from CDC (1998) indicate that secondary prevention measure can reduce the risk
of developing the long-term complications of HCV infection by identifying HCV positive
people and providing appropriate medical treatment and management. This also requires
early placement on the liver transplantation list for those with advanced liver disease.
There is an urgent need to enroll high-risk young adults into substance abuse
treatments and treatment facilities. Such undertaking requires collaboration between
federal organizations such as CDC, working with the state and local health departments to
implement measures to address the parenteral prescription drugs epidemic and HCV
infection. Any intervention to decrease the rates of HCV infection should include educating
different age groups on safe sexual practices, targeting different tattoo parlors, and
increasing the number of needle exchange programs, which targets the PWID. Alter (2002)
had indicated that an effective prevention measure to reduce HCV infection among PWID
would be to nullify the restrictive paraphernalia regulation and increase the number of
needle exchange programs whereby sterile syringes and needles can be made available to
this population. Implementation of needle exchange programs has also be shown to be
effective not only in reducing transmission of HCV infection, but also HCV incidence in
PWID (Des Jarlais et al., 2009; Van Den Berg et al., 2007). Recently, the anti-heroin
legislation (Senate Bill 192) was passed in Kentucky allowing health departments in the
state of Kentucky to establish needle exchange programs where people who use drugs can
exchange their used needles and syringes for clean ones, and also for the state to increase
access to treatment for this population (Cheves, 2015; Wynn, 2015).
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CONCLUSION
In conclusion, this study showed that age and MSM, history of IDU and presence
of tattoos influenced the association between residence in Appalachia vs. Non-Appalachia
and HCV infection in the state of Kentucky. Furthermore, risk factors differ between the
geographic regions of Kentucky. Therefore, reinforced public education and intervention
targeting different gender groups and risky behaviors are required to prevent HCV
infection in the state. Despite the limitations of this study, information was provided on
some risk factors associated with the high prevalence of HCV infection in Kentucky and
the study also highlighted the distribution of HCV infection and its significant associated
variables depending on the region of residence. More research is required to provide a
better understanding of the association between these risky behaviors and HCV infection.
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TABLES AND FIGURES
Table I. Descriptive and Bivariate Analyses of Factors Associated with HCV Antibody
Status
Risk factors

Total
(n=5205)

Anti-HCV
Positive
(n=509)
N (%)

Anti-HCV
Negative
(n=4696)
N (%)

Unadjusted OR
(95% CI)

N (%)
Gender
2964 (56.9)
270 (53.0)
2694 (57.4)
reference
Female
2241 (43.1)
239 (47.0)
2002 (42.6)
1.19 (0.99-1.43)
Male
Race
3952 (75.9)
481 (94.5)
3471 (73.9)
reference
White
1221 (23.5)
27 (5.3)
1194 (25.4)
0.16 (0.11-0.24)
Black
32 (0.6)
1 (0.2)
31 (0.7)
0.23 (0.03-1.71)
Othersa
Ethnicity
297 (5.7)
6 (1.2)
291 (6.2)
reference
Hispanic
4908 (94.3)
503 (98.8)
4405 (93.8)
5.54 (2.46-12.49)
Non-Hispanic
Age (years),
30.4 (10.5)
31.9 (10.2)
30.2 (10.6)
1.02 (1.01-1.02)
mean (SD)
Hx of IDU
4487 (86.2)
112 (22.0)
4375 (93.2)
reference
No
718 (13.8)
397 (78.0)
321 (6.8)
48.31 (38.07-61.32)
Yes
HIV Status
4740 (91.1)
430 (84.5)
4310 (91.8)
reference
Negative
276 (5.3)
51 (10.0)
225 (4.8)
2.27 (1.65-3.13)
Positive
189 (3.6)
28 (5.5)
161 (3.4)
1.74 (1.15-2.64)
Unawareb
Hx Multiple sexual
partners
1086 (20.9)
67 (13.2)
1019 (21.7)
reference
No
4119 (79.1)
442 (86.8)
3677 (78.3)
1.83 (1.40-2.39)
Yes
MSMc
4957 (95.2)
498 (97.8)
4459 (95.0)
reference
No
237 (4.6)
11 (2.2)
226 (4.8)
0.44 (0.24-0.80)
Yes
Tattoosd
2057 (39.5)
121 (23.8)
1936 (41.2)
reference
No
3078 (59.1)
381 (74.8)
2697 (57.4)
2.26 (1.83-2.80)
Yes
Previous STDc
2925 (56.2)
283 (55.6)
2642 (56.3)
reference
No
2269 (43.6)
224 (44.0)
2045 (43.5)
1.02 (0.85-1.23)
Yes
Regional Residence
4996 (96.0)
481 (94.5)
4515 (96.1)
reference
Non-Appalachian
209 (4.0)
28 (5.5)
181 (3.9)
1.45 (0.97-2.19)
Appalachian
SD =standard deviation, Hx = history, IDU = injection drug use, MSM = men who have sex with
men, STD= sexually transmitted diseases, KY = Kentucky, 95% CI = 95% confidence interval
a
Others include Asian and mixed race
b
Participants either did not know their status or that information was missing
c
11 participants had missing data for these variables
d
70 participants had missing data for this variable
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Pvalue

−
0.062
−
0.000
0.152
−
0.000
0.000
−
0.000
−
0.000
0.008
−
0.000
−
0.008
−
0.000
−
0.812
−
0.074

Table II. Final Multivariate Logistic Regression Model Examining Variables Associated
with HCV Antibody Seropositivity
Variables
Regional Residence
Non-Appalachian
Appalachian
Gender
Female
Male
Race
White
Black
Othersa
Age (years)
Hx of IDU
No
Yes
HIV Status
Negative
Positive
Unawareb
Hx Multiple sexual
partners
No
Yes
MSMc
No
Yes
Tattoosd
No
Yes
Appalachian*Gender

Adjusted OR

95% Confidence
Interval (CI)

P-value

reference
1.16

−
0.52-2.62

−
0.713

reference
1.16

−
0.90-1.48

−
0.254

reference
0.42
0.69
1.03

−
0.26-0.66
0.08-6.37
1.02-1.04

−
0.000*
0.744
0.000*

reference
41.27

−
31.94-53.31

−
0.000*

reference
1.37
0.99

−
0.89-2.11
0.50-1.95

−
0.153
0.977

reference
1.31

−
0.94-1.83

−
0.110

reference
0.36

−
0.17-0.73

−
0.005*

reference
1.49
2.52

−
1.14-1.96
0.78-8.19

−
0.004*
0.124

Likelihood Ratio Chi-Square = 1360.076, on 12 df; p-value = 0.000
SD = standard deviation, Hx= history, IDU= injection drug use, MSM= men who have sex with
men
*Indicates statistical significance (p<0.05)
a
Others include Asian and mixed race
b
Participants either did not know their status or that information was missing
c
11 participants had missing data for this variable
d
70 participants had missing data for this variable
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Table III. Variables Associated with HCV Antibody Seropositivity Stratified by
Appalachian and Non-Appalachian Residence
Variables

Appalachian (n=209)
OR (95% CI)
P-value

Non-Appalachian (n=4996)
OR (95% CI)
P-value

Gender
reference
−
reference
−
Female
2.94 (1.30-6.62)
0.009
1.15 (0.95-1.39)
0.147
Male
Race
reference
−
reference
−
White
0.00 (0.00)
0.999
0.17 (0.11-0.25)
0.000
Black
−
−
0.24 (0.03-1.73)
0.155
Othersa
Ethnicity
reference
−
reference
−
Hispanic
−
−
5.45 (2.42-12.31)
0.000
Non-Hispanic
1.00 (0.96-1.04)
0.904
1.02 (1.01-1.02)
0.000
Age (years)
Hx of IDU
reference
−
reference
−
No
54.06 (18.29-159.80)
0.000
48.67 (38.07-62.21)
0.000
Yes
HIV Status
reference
−
reference
−
Negative
2.97 (0.28-31.06)
0.363
2.26 (1.64-3.13)
0.000
Positive
1.78 (0.78-4.06)
0.169
1.49 (0.81-2.75)
0.204
Unawareb
Hx Multiple
sexual partners
reference
−
reference
−
No
2.97 (1.20-7.32)
0.018
1.82 (1.37-2.41)
0.000
Yes
MSMc
reference
−
reference
−
No
2.20 (0.22-21.90)
0.502
0.41 (0.22-0.77)
0.006
Yes
Tattoosd
reference
−
reference
−
No
2.05 (0.86-4.89)
0.104
2.29 (1.84-2.86)
0.000
Yes
Previous STDc
reference
−
reference
−
No
1.45 (0.63-3.36)
0.381
1.01 (0.84-1.22)
0.916
Yes
OR = odds ratio, SD =standard deviation, Hx = history, IDU = injection drug use, MSM = men
who have sex with men, STD= sexually transmitted diseases, KY = Kentucky, 95% CI = 95%
confidence interval
a
Others include Asian and mixed race
b
Participants either did not know their status or that information was missing
c
11 participants had missing data for these variables
d
70 participants had missing data for this variable
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Figure 1. Distribution of HCV positive individuals by county in Kentucky, 2012-2014
(n=5205). The different shades of purple indicate the counties with HCV positive
individuals in increasing numbers. The counties with the highest HCV prevalence are
concentrated in Northern Kentucky. The gray-colored regions include counties that
participated in the statewide survey study but reported no HCV positive individuals. The
white-colored counties include those counties that did not participate in the statewide study.
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APPENDIX
Table IV. Distribution of Variables between Appalachian versus Non-Appalachian
County Residence: Results of Bivariate Analysis
Variables

Appalachian (n=209)
HCV+, N (%)
HCV-, N (%)

Non-Appalachian (n=4996)
HCV+, N (%)
HCV-, N (%)

Gender
14 (50.0)
135 (74.6)
256 (53.2)
2559 (56.7)
Female
14 (50.0)
46 (25.4)
225 (46.8)
1956 (43.3)
Male
Race
28 (100.0)
168 (92.8)
453 (94.2)
3303 (73.2)
White
0 (0.0)
13 (7.2)
27 (5.6)
1181 (26.2)
Black
0 (0.0)
0 (0.0)
1 (0.2)
31 (0.7)
Othersa
Ethnicity
0 (0.0)
0 (0.0)
6 (1.2)
291 (6.4)
Hispanic
28 (100.0)
181 (100.0)
475 (98.8)
4224 (93.6)
Non-Hispanic
Age (years),
30.0 (6.0)
30.0 (11.0)
32.0 (10.0)
30.0 (11.0)
mean (SD)
Hx of IDU
8 (28.6)
173 (95.6)
104 (21.6)
4202 (93.1)
No
20 (71.4)
8 (4.4)
377 (78.4)
313 (6.9)
Yes
HIV Status
11 (39.3)
98 (54.1)
419 (87.1)
4212 (93.3)
Negative
1 (3.6)
3 (1.7)
50 (10.4)
222 (4.9)
Positive
b
16
(57.1)
80
(44.2)
12
(2.5)
81 (1.8)
Unaware
Hx Multiple
sexual partners
7 (25.0)
90 (49.7)
60 (12.5)
929 (20.6)
No
21 (75.0)
91 (50.3)
421 (87.5)
3586 (79.4)
Yes
MSMc
27 (96.4)
178 (98.3)
471 (97.9)
4281 (95.0)
No
1 (3.6)
3 (1.7)
10 (2.1)
223 (5.0)
Yes
Tattoosd
9 (36.0)
97 (53.6)
112 (23.5)
1839 (41.3)
No
16 (64.0)
84 (46.4)
365 (76.5)
2613 (58.7)
Yes
Previous STDc
15 (57.7)
119 (66.5)
268 (55.7)
2523 (56.0)
No
11 (42.3)
60 (33.5)
213 (44.3)
1985 (44.0)
Yes
SD =standard deviation, Hx = history, IDU = injection drug use, MSM = men who have sex with
men, STD= sexually transmitted diseases, KY = Kentucky
a
Others include Asian and Mixed race
b
Participants either did not know their status or that information was missing
c
11 participants had missing data for these variables
d
70 participants had missing data for this variable
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Table V. Assessing Interaction in the Association between Appalachian versus NonAppalachian Residence and HCV Antibody Seropositivity: Results of Bivariate Analysis
Variablesa

OR

95% CI

P-value

Appalachian

1.45

0.97-2.19

0.074

Appalachian*Gender

2.55

1.11-5.88

0.028*

Appalachian*Age (years)

0.98

0.95-1.02

0.371

Appalachian*Hx of IDU

1.11

0.37-3.38

0.853

0.85

0.54-1.35

0.495

Appalachian*Hx Multiple sexual
partners
Appalachian*MSMc

1.63

0.63-4.20

0.310

5.39

0.50-58.65

0.166

Appalachian*Tattoosd

0.90

0.37-2.19

0.808

1.44

0.61-3.40

0.405

e

Appalachian*HIV status

b

c

Appalachian*Previous STD

Hx = history, IDU = injection drug use, MSM = men who have sex with men, STD= sexually
transmitted diseases, OR = odds ratio, 95% CI = 95% confidence interval
*Interaction present
a
Race and ethnicity variables were excluded because they contained stratified cell sizes too small
(i.e. cell sizes of zero) to be analyzed in interaction terms
b
189 participants either did not know their status or that information was missing
c
11 participants had missing data for these variables
d
70 participants had missing data for this variable
e
Non-Appalachian residence was the reference group

Table VI. Assessing Confounding in the Association between Appalachian versus NonAppalachian Residence and HCV Antibody Seropositivity: Results of Bivariate Analysis
Variables

OR†

95% CI

P-value

a

Appalachian

1.45

0.97-2.19

0.074

Appalachian + Gender

1.49

0.99-2.25

0.055

Appalachian + Race

1.20*

0.79-1.81

0.391

Appalachian + Ethnicity

1.38

0.91-2.07

0.127

Appalachian + Age (years)

1.47

0.97-2.21

0.067

Appalachian + Hx of IDU

1.96*

1.14-3.37

0.015

1.22*

0.75-1.96

0.421

Appalachian + Hx Multiple sexual
partners
Appalachian + MSMc

1.70*

1.12-2.58

0.012

1.43

0.95-2.15

0.090

Appalachian + Tattoosd

1.42

0.92-2.19

0.113

1.37

0.90-2.08

0.149

Appalachian + HIV status

b

Appalachian + Previous STD

c

Hx= history, IDU = injection drug use, MSM= men who have sex with men, STD= sexually
transmitted diseases, OR = odds ratio, 95% CI = 95% confidence interval
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*Confounding factors present, as indicated in 15% or greater change in AOR
a
Non-Appalachian residence was the reference group
b
189 participants either did not know their status or that information was missing
c
11 participants had missing data for these variables
d
70 participants had missing data for this variable
†
Odds ratios are displayed for the association between Appalachian residence and HCV status,
adjusting for the variable listed in Column 1, where applicable

Table VII: Socio-demographic Characteristics across Age Groups, 2012-2014
Tested (n=5205)
Characteristics
Age Group (years)
10-19
20-29
30-39
40-49
50-59
60-69
70-79
80+

N (%)

Screened HCV+
(n=509)
N (%)

Screened HCV(n=4696)
N (%)

459 (8.8)
2575 (49.5)
1224 (23.5)
566 (10.9)
302 (5.8)
68 (1.3)
8 (0.2)
3 (0.1)

17 (3.3)
247 (48.5)
142 (27.9)
60 (11.8)
38 (7.5)
4 (0.8)
1 (0.2)
0 (0.0)

442 (9.4)
2328 (49.6)
1082 (23.0)
506 (10.8)
264 (5.6)
64 (1.4)
7 (0.1)
3 (0.1)

Table VIII. Association between Variables and HCV Infection Stratified by Gender,
2012–2014
Variables

Male (n=2241)
OR (95% CI)
P-value
1.02 (1.01-1.03)
0.005

Female (n=2964)
OR (95% CI)
P-value
1.01 (1.00-1.02)
0.058

Age (years)
Hx Multiple
sexual partners
reference
−
reference
No
1.20 (0.82-1.76)
0.342
2.45 (1.69-3.57)
Yes
Hx of IDU
reference
−
reference
No
49.03 (34.41-69.85)
0.000
47.57 (34.45-65.68)
Yes
Hx = history, IDU = injection drug use, OR = odds ratio, 95% CI = 95% confidence interval
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−
0.000
−
0.000
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